150 related articles for article (PubMed ID: 14624783)
1. The 'angiogenic switch' in the progression from Barrett's metaplasia to esophageal adenocarcinoma.
Möbius C; Stein HJ; Becker I; Feith M; Theisen J; Gais P; Jütting U; Siewert JR
Eur J Surg Oncol; 2003 Dec; 29(10):890-4. PubMed ID: 14624783
[TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor expression and neovascularization in Barrett's carcinoma.
Möbius C; Stein HJ; Becker I; Feith M; Theisen J; Gais P; Jütting U; Siewert JR
World J Surg; 2004 Jul; 28(7):675-9. PubMed ID: 15175900
[TBL] [Abstract][Full Text] [Related]
3. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation.
Chinyama CN; Marshall RE; Owen WJ; Mason RC; Kothari D; Wilkinson ML; Sanderson JD
Histopathology; 1999 Dec; 35(6):517-24. PubMed ID: 10583575
[TBL] [Abstract][Full Text] [Related]
4. COX-2, CDX2, and CDC2 immunohistochemical assessment for dysplasia-carcinoma progression in Barrett's esophagus.
Villanacci V; Rossi E; Zambelli C; Galletti A; Cestari R; Missale G; Casa DD; Bassotti G
Dig Liver Dis; 2007 Apr; 39(4):305-11. PubMed ID: 17307036
[TBL] [Abstract][Full Text] [Related]
5. Proinflammatory cytokine and nuclear factor kappa-B expression along the inflammation-metaplasia-dysplasia-adenocarcinoma sequence in the esophagus.
O'Riordan JM; Abdel-latif MM; Ravi N; McNamara D; Byrne PJ; McDonald GS; Keeling PW; Kelleher D; Reynolds JV
Am J Gastroenterol; 2005 Jun; 100(6):1257-64. PubMed ID: 15929754
[TBL] [Abstract][Full Text] [Related]
6. Activation of Wnt signalling promotes development of dysplasia in Barrett's oesophagus.
Moyes LH; McEwan H; Radulescu S; Pawlikowski J; Lamm CG; Nixon C; Sansom OJ; Going JJ; Fullarton GM; Adams PD
J Pathol; 2012 Sep; 228(1):99-112. PubMed ID: 22653845
[TBL] [Abstract][Full Text] [Related]
7. Autocrine VEGF signaling promotes proliferation of neoplastic Barrett's epithelial cells through a PLC-dependent pathway.
Zhang Q; Yu C; Peng S; Xu H; Wright E; Zhang X; Huo X; Cheng E; Pham TH; Asanuma K; Hatanpaa KJ; Rezai D; Wang DH; Sarode V; Melton S; Genta RM; Spechler SJ; Souza RF
Gastroenterology; 2014 Feb; 146(2):461-72.e6. PubMed ID: 24120473
[TBL] [Abstract][Full Text] [Related]
8. In situ hybridization for the detection of telomerase RNA in the progression from Barrett's esophagus to esophageal adenocarcinoma.
Morales CP; Lee EL; Shay JW
Cancer; 1998 Aug; 83(4):652-9. PubMed ID: 9708927
[TBL] [Abstract][Full Text] [Related]
9. p53 protein accumulation in Barrett's metaplasia, dysplasia, and carcinoma: a follow-up study.
Younes M; Lebovitz RM; Lechago LV; Lechago J
Gastroenterology; 1993 Dec; 105(6):1637-42. PubMed ID: 8253340
[TBL] [Abstract][Full Text] [Related]
10. Usefulness of insulin-like growth factor II mRNA-binding protein 3 (IMP3) as a new marker for the diagnosis of esophageal adenocarcinoma in challenging cases.
Kazeminezhad B; Mirafsharieh SA; Dinyari K; Azizi D; Ebrahimi A
Turk J Gastroenterol; 2014 Jun; 25(3):253-6. PubMed ID: 25141312
[TBL] [Abstract][Full Text] [Related]
11. High-grade dysplasia and superficial adenocarcinoma in Barrett's esophagus: histological mapping and expression of p53, p21 and Bcl-2 oncoproteins.
Chatelain D; Fléjou JF
Virchows Arch; 2003 Jan; 442(1):18-24. PubMed ID: 12536310
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
13. Increasing expression of hypoxia-inducible proteins in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence.
Griffiths EA; Pritchard SA; McGrath SM; Valentine HR; Price PM; Welch IM; West CM
Br J Cancer; 2007 May; 96(9):1377-83. PubMed ID: 17437013
[TBL] [Abstract][Full Text] [Related]
14. Apoptosis and cell proliferation in the metaplasia-dysplasia-carcinoma-sequence of Barrett's esophagus.
Halm U; Tannapfel A; Breitung B; Breidert M; Wittekind CW; Mössner J
Hepatogastroenterology; 2000; 47(34):962-6. PubMed ID: 11020858
[TBL] [Abstract][Full Text] [Related]
15. Transforming growth factor-alpha, epidermal growth factor receptor, and MiB-1 expression in Barrett's-associated neoplasia: correlation with prognosis.
Yacoub L; Goldman H; Odze RD
Mod Pathol; 1997 Feb; 10(2):105-12. PubMed ID: 9127315
[TBL] [Abstract][Full Text] [Related]
16. Pericentriolar material analyses in normal esophageal mucosa, Barrett's metaplasia and adenocarcinoma.
Segat D; Cassaro M; Dazzo E; Cavallini L; Romualdi C; Salvador R; Vitale MP; Vitiello L; Fassan M; Rugge M; Zaninotto G; Ancona E; Baroni MD
Histol Histopathol; 2010 May; 25(5):551-60. PubMed ID: 20238294
[TBL] [Abstract][Full Text] [Related]
17. The diagnosis and management of Barrett's esophagus.
DeMeester SR; DeMeester TR
Adv Surg; 1999; 33():29-68. PubMed ID: 10572561
[TBL] [Abstract][Full Text] [Related]
18. Time gated fluorescence spectroscopy in Barrett's oesophagus.
Ortner MA; Ebert B; Hein E; Zumbusch K; Nolte D; Sukowski U; Weber-Eibel J; Fleige B; Dietel M; Stolte M; Oberhuber G; Porschen R; Klump B; Hörtnagl H; Lochs H; Rinneberg H
Gut; 2003 Jan; 52(1):28-33. PubMed ID: 12477755
[TBL] [Abstract][Full Text] [Related]
19. Malignant degeneration of Barrett's esophagus: the role of the Ki-67 proliferation fraction, expression of E-cadherin and p53.
Feith M; Stein HJ; Mueller J; Siewert JR
Dis Esophagus; 2004; 17(4):322-7. PubMed ID: 15569371
[TBL] [Abstract][Full Text] [Related]
20. Association of manganese superoxide dismutase expression with progression of carcinogenesis in Barrett esophagus.
Hermann B; Li Y; Ray MB; Wo JM; Martin RC
Arch Surg; 2005 Dec; 140(12):1204-9; discussion 1209. PubMed ID: 16365243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
